Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
| Autor: | Frank Jühling, Yujin Hoshida, Atsushi Ono, Thomas F. Baumert |
|---|---|
| Přispěvatelé: | Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), L'Institut hospitalo-universitaire de Strasbourg (IHU Strasbourg), Institut National de Recherche en Informatique et en Automatique (Inria)-l'Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD)-Les Hôpitaux Universitaires de Strasbourg (HUS)-La Fédération des Crédits Mutuels Centre Est (FCMCE)-L'Association pour la Recherche contre le Cancer (ARC)-La société Karl STORZ, Nouvel Hôpital Civil de Strasbourg, Icahn School of Medicine at Mount Sinai [New York] (MSSM), Hiroshima University, univOAK, Archive ouverte |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Liver Cirrhosis Hepatocellular carcinoma Aucun Hepacivirus medicine.disease_cause Direct-acting antivirals Local/drug therapy/virology Hepacivirus/physiology 0302 clinical medicine Interferon Liver Cirrhosis/drug therapy/pathology/virology Genotype Sustained virologic response Medicine(all) [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology Interferons/therapeutic use Hepatitis C virus Incidence (epidemiology) Liver Neoplasms General Medicine Hepatitis C 3. Good health Antiviral Agents/*therapeutic use 030211 gastroenterology & hepatology medicine.drug Carcinoma Hepatocellular Liver Neoplasms/*drug therapy/epidemiology/*virology Sciences du Vivant [q-bio]/Médecine humaine et pathologie Hepatitis C/*complications/*drug therapy Antiviral Agents 03 medical and health sciences Diabetes mellitus medicine Carcinoma Humans Hepatocellular/*drug therapy/*virology business.industry medicine.disease Neoplasm Recurrence 030104 developmental biology Immunology Minireview Interferons Neoplasm Recurrence Local business [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| Zdroj: | BMC Medicine BMC Medicine, BioMed Central, 2017, 15 (1), ⟨10.1186/s12916-017-0815-7⟩ BMC Medicine, 2017, 15 (1), ⟨10.1186/s12916-017-0815-7⟩ |
| ISSN: | 1741-7015 |
| DOI: | 10.1186/s12916-017-0815-7⟩ |
| Popis: | PMC5348895; Hepatitis C virus infection is a major cause of hepatocellular carcinoma worldwide. Interferon has been the major antiviral treatment, yielding viral clearance in approximately half of patients. New direct-acting antivirals substantially improved the cure rate to above 90%. However, access to therapies remains limited due to the high costs and under-diagnosis of infection in specific subpopulations, e.g., baby boomers, inmates, and injection drug users, and therefore, hepatocellular carcinoma incidence is predicted to increase in the next decades even in high-resource countries. Moreover, cancer risk persists even after 10 years of viral cure, and thus a clinical strategy for its monitoring is urgently needed. Several risk-predictive host factors, e.g., advanced liver fibrosis, older age, accompanying metabolic diseases such as diabetes, persisting hepatic inflammation, and elevated alpha-fetoprotein, as well as viral factors, e.g., core protein variants and genotype 3, have been reported. Indeed, a molecular signature in the liver has been associated with cancer risk even after viral cure. Direct-acting antivirals may affect cancer development and recurrence, which needs to be determined in further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|